LISCure Biosciences Inc., a biotech company that focuses on developing bacteria-mediated immunotherapy, has completed $21 million of a Series B funding round. Participants include institutional investors, venture capitals, and KOSDAQ listed companies (as strategic investors). This funding round will help LISCure further develop its pipeline and enhance its R&D capabilities of key technologies. It is…